Our findings reveal PRDX1 as a central regulator of the metabolic crosstalk between CRC cells and TAMs in TME, highlighting its potential as a novel therapeutic target to overcome immunosuppression in CRC. This evidence concerns the gene PRDX1 and colorectal carcinoma.